Life Sciences

  • January 07, 2026

    Detroit Pension Fund Wins 'Close' Call To Lead Investor Suit

    A Detroit pension fund should lead a proposed shareholder class action against MoonLake Immunotherapeutics, though a competing bid by a France-based lab worker and screenwriter alleges a "marginally larger" investment loss, a Manhattan federal judge has determined.

  • January 06, 2026

    Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties

    Bayer wants a cut of the profits Johnson & Johnson, Moderna, Pfizer and BioNTech have reaped from sales of their COVID-19 vaccines, which the German biotech company alleges were only made possible through infringement of its intellectual property, according to lawsuits filed Tuesday in New Jersey and Delaware federal courts.

  • January 06, 2026

    Cigna Accused Of Rigging Market For Life-Saving Drugs

    Patients with chronic health conditions sued Cigna in an Illinois federal court alleging in a proposed class action Tuesday that the company and its pharmacy and pharmacy benefit manager subsidiaries use exclusive agreements to lock users into a network where Byzantine refill processes have been deliberately erected to limit payouts for life-saving drugs.

  • January 06, 2026

    FDA To Ease Regulation Of Wearables, Decision Software

    U.S. Food and Drug Administration Commissioner Marty Makary touted new federal guidance on Tuesday that he said would promote innovation by making it easier to bring certain kinds of wearable devices and clinical-decision software to market without a strict regulatory review.

  • January 06, 2026

    1st Circ. Questions Feds' Mootness Claim In NIH Grant Suits

    The First Circuit appeared to push back Tuesday on assertions by the government that new guidance for terminating medical research grants over supposed links to issues like DEI, gender identity and vaccines — along with a partial settlement last week — moot a pair of lawsuits challenging the directives.

  • January 06, 2026

    RFK Jr. Can't Avoid Medical Groups' Challenge To Vax Policy

    A Boston federal judge on Tuesday rebuffed U.S. Health and Human Services Secretary Robert F. Kennedy Jr.'s bid to dismiss a challenge to vaccine policy changes, saying medical associations have plausibly alleged a federal vaccine committee is not fairly balanced.

  • January 06, 2026

    NJ Judge Signals Green Light To Revive J&J Unit's Libel Suit

    A New Jersey federal judge has indicated she is planning to grant a bankrupt Johnson & Johnson talc subsidiary's bid to revive its trade libel claim over a scientific article linking asbestos in talc to mesothelioma.

  • January 06, 2026

    Public Health Atty Talks Botulism, Infants And FDA Staffing

    Three years ago, a bacterial outbreak at a Michigan manufacturing plant sparked a shutdown and a national infant formula shortage. Another episode last year at a formula plant in Iowa should be a red flag for the public and a short-handed FDA, according to Sarah Sorscher of the Center for Science in the Public Interest.

  • January 06, 2026

    Drugmakers Fight Multifront Legal Battles Over GLP-1s

    In the wake of U.S. Food and Drug Administration approvals for GLP-1 weight-loss drugs, surging public demand and massive profits have inspired a broad range of drugmaker litigation against competitors, alleged counterfeits and telehealth providers.

  • January 06, 2026

    Wyo. High Court Strikes Down 2 Laws Restricting Abortion

    The Wyoming Supreme Court struck down the state's near-total abortion ban and a first-of-its-kind prohibition on abortion pills on Tuesday, saying the laws violated the state constitution.

  • January 06, 2026

    Ill. Judge Trims Most Of Walgreens Shareholder Suit

    An Illinois federal judge on Monday dismissed most claims in a lawsuit alleging Walgreens inflated share prices by concealing the lack of viability of its pharmacy division and primary care investment, warning shareholders not to "waste judicial resources" in amending their allegations by claiming straightforward statements are misleading "absent a coherent argument as to why."

  • January 06, 2026

    Healthcare Litigator Moves Practice To Troutman In Philly

    A litigator specializing in healthcare and product liability cases has joined Troutman Pepper Locke LLP's Philadelphia office after practicing for more than six years with Campbell Conroy & O'Neil PC.

  • January 06, 2026

    Federal Prosecutor Rejoins King & Spalding In Atlanta

    A former federal prosecutor who left King & Spalding LLP five years ago for an assistant U.S. attorney role has returned to the firm as an Atlanta-based partner in its product liability and mass torts practice, according to a Tuesday announcement.

  • January 06, 2026

    Top Personal Injury, Medical Malpractice Cases Of 2025

    A headline-grabbing $329 million wrongful death verdict against Tesla and a landmark $2.5 billion deal between DuPont and New Jersey over PFAS "forever chemicals" are among Law360's top personal injury and medical malpractice cases from 2025.

  • January 05, 2026

    1st Circ. Upholds Block On Trump Admin NIH Funding Cuts

    The First Circuit on Monday affirmed a Massachusetts federal judge's order permanently blocking the Trump administration from gutting National Institutes of Health funding for biomedical research, agreeing that the government didn't have the authority to cap indirect costs for research grants.

  • January 05, 2026

    Fed. Circ. Examines Timing Of $452M Trade Secrets Suit

    A Federal Circuit panel delved into the statute of limitations for trade secrets cases Monday, pressing an attorney for a South Korean company seeking to reverse a verdict that prompted a $452 million jury award to explain why the clock should start when a plaintiff suspects misappropriation rather than when it is actually discovered.

  • January 05, 2026

    Express Scripts Wants FTC Atty Views On Insulin Prices

    Express Scripts is seeking to force an attorney from the Federal Trade Commission to sit for a deposition in the agency's case accusing pharmacy benefit managers of inflating insulin prices, saying the commission's own attorneys acknowledge that manufacturers cause higher prices.

  • January 05, 2026

    Cancer Biotech Co. Eyes $182M IPO

    A company developing new drugs for treating cancer disclosed Monday it is looking to raise roughly $182 million in an initial public offering guided by Paul Hastings LLP and Davis Polk & Wardwell LLP, teeing it up for the first major IPO of 2026.

  • January 05, 2026

    Aetna Drug Price-Fixing Suit Against Pharma Cos. Paused

    A judge has paused Aetna Inc.'s Connecticut Superior Court lawsuit accusing nearly two dozen pharmaceutical companies of fixing the prices of generic drugs, refusing drugmakers' bids to dismiss the case but agreeing to put it on hold pending the outcomes of similar cases in other jurisdictions.

  • January 05, 2026

    3rd Circ. Won't Rethink Tax On Interest In $191M Pharma Deal

    The Third Circuit declined to reconsider its decision that a pharmaceutical company's $191 million payment settling a family feud was for the sale of a family trust's ownership shares and included interest that should be taxed as ordinary income.

  • January 05, 2026

    Health Officials Roll Back Child Vaccine Recommendations

    Amid public outcry, federal health officials on Monday revised vaccine recommendations for American children, cutting the number from 18 to 11 and bringing the United States in line with other developed countries such as Denmark. 

  • January 05, 2026

    Ind. Sues Eli Lilly Over 'Grossly Inflated' Insulin Prices

    Indiana's attorney general on Monday announced a state court suit against Eli Lilly alleging it schemed to artificially inflate the price of insulin, saying the litigation follows two years of ultimately unsuccessful attempts to resolve the matter without litigation against the drug manufacturer.

  • January 05, 2026

    Trump Backs Biden's Medicare Drug Price Law At High Court

    The Trump administration is defending the Biden-era Medicare Drug Price Negotiation program to the U.S. Supreme Court, asking the justices to deny AstraZeneca's petition challenging the program as unconstitutional.

  • January 05, 2026

    Thesis Supplements Illegally Sold As ADHD Drugs, Suit Says

    A Louisiana woman is suing the owner of Thesis Nootropics in New York federal court, alleging that the company's line of supplements is illegally marketed as an alternative to Adderall and other medications despite lacking federal approval.

  • January 05, 2026

    Paul Hastings Adds Hogan Lovells Duo To Life Sciences Team

    Two longtime Hogan Lovells partners, including the head of its pharmaceutical and biotechnology regulatory practice, have joined Paul Hastings LLP in Washington, D.C., the firm announced Monday.

Expert Analysis

  • Series

    Adapting To Private Practice: 3 Tips On Finding The Right Job

    Author Photo

    After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.

  • Series

    Painting Makes Me A Better Lawyer

    Author Photo

    Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.

  • Courts Are Still Grappling With McDonnell, 9 Years Later

    Author Photo

    The Seventh and D.C. Circuits’ recent decisions in U.S. v. Weiss and U.S. v. Paitsel, respectively, demonstrate that courts are still struggling to apply the U.S. Supreme Court’s 2016 ruling in McDonnell v. U.S., which narrowed the scope of “official acts” in federal bribery cases, say attorneys at Quinn Emanuel.

  • AI Will Transform Patent Examination For The Better

    Author Photo

    The U.S. Patent and Trademark Office's increasing use of artificial intelligence tools will result in patents that are more thoroughly vetted, and patent applicants and practitioners will need to adapt their drafting strategies and address stronger and more sophisticated rejections, say attorneys at Troutman.

  • Hybrid Claims In Antitrust Disputes Spark Coverage Battles

    Author Photo

    Antitrust litigation increasingly includes claims for breach of warranty, product liability or state consumer protection violations, complicating insurers' reliance on exclusions as courts analyze whether these are antitrust claims in disguise, says Jameson Pasek at Caldwell Law.

  • Drug Ad Crackdown Demonstrates Admin's Aggressive Stance

    Author Photo

    Recent actions by the U.S. Food and Drug Administration and U.S. Department of Health and Human Services targeting pharmaceutical companies' allegedly deceptive advertising practices signal an active — potentially even punitive — intent to regulate direct-to-consumer advertising out of existence, say attorneys at King & Spalding.

  • Protecting Sensitive Court Filings After Recent Cyber Breach

    Author Photo

    In the wake of a recent cyberattack on federal courts' Case Management/Electronic Case Files system, civil litigants should consider seeking enhanced protections for sensitive materials filed under seal to mitigate the risk of unauthorized exposure, say attorneys at Redgrave.

  • Series

    Judging Figure Skating Makes Me A Better Lawyer

    Author Photo

    Judging figure skating competitions helps me hone the focus, decisiveness and ability to process complex real-time information I need in court, but more importantly, it makes me reengage with a community and my identity outside of law, which, paradoxically, always brings me back to work feeling restored, says Megan Raymond at Groombridge Wu.

  • Trending At The PTAB: Petitioners' Settled Expectations

    Author Photo

    Recent Patent Trial and Appeal Board decisions show that the U.S. Patent and Trademark Office's new "settled expectations" factor is no longer the exclusive domain of patent owners and can also provide petitioners with viable pathways to argue against discretionary denial, say attorneys at Finnegan.

  • 9th Circ. Ruling May Help Pharma Cos. Avert Investor Claims

    Author Photo

    The Ninth Circuit's recent decision affirming the dismissal of a securities fraud class action alleging that Talphera deceived investors by marketing a drug with a misleading slogan should give plaintiffs pause before filing similar complaints where snappy slogans are accompanied by copious clarifying information, say attorneys at Simpson Thacher.

  • What Ethics Rules Say On Atty Discipline For Online Speech

    Author Photo

    Though law firms are free to discipline employees for their online commentary about Charlie Kirk or other social media activity, saying crude or insensitive things on the internet generally doesn’t subject attorneys to professional discipline under the Model Rules of Professional Conduct, says Stacie H. Rosenzweig at Halling & Cayo.

  • Junior Attys Must Beware Of 5 Common Legal Brief Mistakes

    Excerpt from Practical Guidance
    Author Photo

    Junior law firm associates must be careful to avoid five common pitfalls when drafting legal briefs — from including every possible argument to not developing a theme — to build the reputation of a sought-after litigator, says James Argionis at Cozen O'Connor.

  • Opinion

    State AGs, Not Local Officials, Should Lead Public Litigation

    Author Photo

    Local governments’ public nuisance lawsuits can raise constitutional and jurisdictional challenges, reinforcing the principle that state attorneys general — not municipalities — are best positioned to litigate on behalf of citizens when it is warranted, says former Utah Attorney General John Swallow.

  • 3rd Circ. Clarifies Ch. 11 3rd-Party Liability Scope Post-Purdue

    Author Photo

    A recent Third Circuit decision that tort claims against the purchaser of a debtor's business belong to the debtor's bankruptcy estate reinvigorates the use of Chapter 11 for the resolution of nondebtor liability in mass tort bankruptcies following last year's U.S. Supreme Court ruling in Purdue Pharma, say attorneys at Sullivan & Cromwell.

  • Texas Suit Marks Renewed Focus On Service Kickback Theory

    Author Photo

    After a dormant period at the federal level, a theory of kickback enforcement surrounding nurse educator programs and patient support services resurfaced with a recent state court complaint filed by Texas against Eli Lilly, highlighting for drugmakers the ever-changing nature of enforcement priorities and industry landscapes, say attorneys at Sheppard Mullin.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.